Treatment | Median (range) number of WBC | p Value |
LPS+/+ mice | ||
IgG-NHS | 1 (0–3) | |
IgG-APS-1* | 6 (4–9) | 0.003 |
IgG-APS-2† | 6 (4–7) | 0.004 |
IgG-SLE | 1 (0–1) | |
Anti-β2GPI depleted IgG-APS-2 | 1 (0–1) | |
LPS−/− mice | ||
IgG-NHS | 0 (0–1) | |
IgG-APS-1* | 1 (0–2) | |
IgG-APS-2† | 1 (0–2) | |
IgG-SLE | 0 (0–0) | |
Anti-β2GPI depleted IgG-APS-2 | 1 (0–2) |
WBC, white blood cell; LPS, lipopolysaccharide; APS, antiphospholipid syndrome; NHS, normal healthy serum; SLE, systemic lupus erythematosus; β2GPI, β2glycoprotein I.
*p = 0.003 for comparison between groups with IgG-APS-1 injected into LPS +/+ vs LPS−/− mice.
†p = 0.004 for comparison between groups with IgG-APS-2 injected into LPS+/+ vs LPS−/− mice.